News

Stryker Expands LFIT V40 Safety Notification

Metal-on-metal hip implants manufactured by Stryker Orthopedics have been the subject of safety alerts and recalls in the past several years. Since the company’s August 2016 notification concerning its LFIT V40 femoral head, indicating a higher-than-expected number of complaints concerning the device, Stryker has expanded its safety notification to include eight additional products that include the device. Problems with the Stryker device may include pain associated with device loosening, dislocation, fracture, leg length discrepancy, inflammation, and pain requiring revision surgery.

If you or a loved one has experienced complications after receiving a metal-on-metal hip implant, please contact us by calling us at 877-790-3588 for a confidential evaluation of your potential claim.

“60 Minutes” Reports on Unsafe Gynecological Mesh Plastic

Over 100,000 women have filed more than 48,000 lawsuits alleging that Boston Scientific’s gynecological mesh inflicts serious pain and injury. The mesh product is a plastic implant designed to relieve urinary incontinence and support organs post-pregnancy. According to a “60 Minutes” report that aired in May 2018, these lawsuits “make up the largest multi-district litigation since asbestos.” Experts consulted for the program said that the plastic in the mesh used by Boston Scientific was provided by a broker in China, and is unsafe for the human body. “I can’t, in my wildest imagination, imagine anybody that’s knowledgeable in the science of plastics ever deciding that it was appropriate to use polypropylene in the human body,” said plastics engineer, Duane Priddy. Patients described their side-effects from the device to include inflammatory reactions and “shooting, uncomfortable pain.”

FDA Takes New Measures to Inform Women of Essure Risks

In April 2018, a national movement of women suffering from painful side effects caused by Essure achieved two major victories: On April 9th, the FDA ruled that health care providers can no longer implant Essure unless the doctor and patient review and sign an FDA-approved document outlining the risks. The following week, the FDA announced new guidelines in approving medical devices for U.S. patients.

FDA Commissioner Scott Gottlieb noted that some women receiving Essure have not been fully informed about the risks associated with it: “Despite previous efforts to alert women to the potential complications of Essure, we know that some patients still aren’t receiving this important information.”  Even with warnings in place, Essure is still available in the U.S., though it has been removed from the market in other countries.

If you or a loved one has been hurt by the Essure implant, please call our attorneys at 888-985-7228 for a confidential evaluation of your potential claim.

First Biomet M2a Metal-on-Metal Hip Trial Scheduled for September 2018

A Fort Lauderdale, Florida court will hear Biomet’s first trial concerning its M2a-Magnum metal-on-metal hip replacement device in September 2018. Like many other complaints lodged against metal-on-metal hip implant manufacturers, recipients of the Biomet device claim to have suffered injuries such as tissue damage and progressive pain leading to device replacement.

If you or a loved one has experienced complications after receiving a metal-on-metal hip implant, please contact us by calling us at 877-790-3588 for a confidential evaluation of your potential claim.

FDA Releases Statement on Essure Review

On March 7, 2018, FDA Commissioner Scott Gottlieb released a statement regarding the agency’s ongoing monitoring and investigations into issues related to Bayer‘s controversial birth control device Essure. More than 750,000 women have received the implant since Essure’s approval in 2002. As of December 31, 2017, the FDA has received 26,773 medical device reports related to Essure describing adverse events such as such as abdominal pain, abnormal uterine bleeding and device migration. In the statement, Mr. Gottlieb noted that the FDA is working to gain more information on the influx reports.

In response to the medical device reports, the FDA first convened a panel of medical experts in the fall of 2015 to better understand concerns regarding Essure. In February 2016, the agency ordered Bayer to conduct a postmarketing study to evaluate the device’s safety. Later that year, the FDA mandated that a black box warning be added to Essure’s labeling and a Patient Decision Checklist be discussed between physicians and their patients to inform patients of the risks of the device. Last September, Bayer halted sales of Essure outside the US.

If you or a loved one suffered complications after receiving an Essure implant, please contact us by calling us at 888-985-7228 for a confidential evaluation of your potential claim.

Real Time Analytics